Dimensional Fund Advisors LP Sells 21,068 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Dimensional Fund Advisors LP decreased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 641,213 shares of the medical instruments supplier’s stock after selling 21,068 shares during the quarter. Dimensional Fund Advisors LP’s holdings in LeMaitre Vascular were worth $52,759,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. YHB Investment Advisors Inc. acquired a new position in LeMaitre Vascular in the 1st quarter valued at approximately $36,000. GAMMA Investing LLC raised its holdings in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 199 shares in the last quarter. West Oak Capital LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at approximately $58,000. nVerses Capital LLC raised its holdings in LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares in the last quarter. Finally, Van ECK Associates Corp acquired a new position in LeMaitre Vascular in the 2nd quarter valued at approximately $75,000. Institutional investors own 84.64% of the company’s stock.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. Insiders sold 43,251 shares of company stock valued at $3,714,994 in the last three months. Corporate insiders own 10.79% of the company’s stock.

Analysts Set New Price Targets

LMAT has been the subject of several recent research reports. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. JMP Securities upped their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Finally, Barrington Research reissued an “outperform” rating and issued a $92.00 target price on shares of LeMaitre Vascular in a report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.40.

LeMaitre Vascular Trading Up 1.6 %

Shares of LMAT opened at $91.71 on Friday. LeMaitre Vascular, Inc. has a 1 year low of $44.27 and a 1 year high of $92.90. The stock has a 50 day simple moving average of $87.29 and a 200-day simple moving average of $78.81. The stock has a market cap of $2.06 billion, a PE ratio of 60.74, a PEG ratio of 2.41 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. During the same period in the prior year, the firm posted $0.37 EPS. LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.70%. LeMaitre Vascular’s dividend payout ratio is 42.38%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.